Skip Navigation

British Journal of Anaesthesia 2007 99(5):603-606; doi:10.1093/bja/aem276
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zaugg, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zaugg, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Board of Management and Trustees of the British Journal of Anaesthesia 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Is protection by inhalation agents volatile? Controversies in cardioprotection

The first 150 words of the full text of this article appear below.

The old Latin saying ‘nomen est omen’ suggests that a name is indicative of, or notorious for, its true but hidden nature. Likewise, current clinical evidence on organ protection elicited by ether-derived inhalation agents (‘anaesthetic preconditioning’) appears volatile or, to say the least, not fully convincing. In this issue of the British Journal of Anaesthesia, Piriou and colleagues1 report on sevoflurane preconditioning in patients undergoing on-pump coronary artery bypass graft (CABG) surgery. Despite some postoperative functional improvement, the primary outcome measure troponin I and some molecular markers of an effective preconditioning process in the heart remained unaffected. These rather disappointing results conflict, at least in part, with previous more promising clinical reports2–6 and call for clarification.

Motivated by the work of Verdouw and colleagues7 and Reimer and colleagues,8 Murry and colleagues9 described for the first time in 1986 the phenomenon termed ‘ischaemic preconditioning’ in canine myocardium. Since then, this . . . [Full Text of this Article]

Declaration of Interest

M. Zaugg

Cardiovascular Anesthesia Research Laboratory
Institute of Anesthesiology
E–HOF, University Hospital Zurich and
Zurich Center of Integrative Human Physiology, ZIHP
University of Zurich
Rämistrasse 100 CH-8091
Zurich
Switzerland

E-mail: michael.zaugg@usz.ch


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
J. Feng, E. Lucchinetti, G. Fischer, M. Zhu, K. Zaugg, M. C. Schaub, and M. Zaugg
Cardiac remodelling hinders activation of cyclooxygenase-2, diminishing protection by delayed pharmacological preconditioning: role of HIF1{alpha} and CREB
Cardiovasc Res, April 1, 2008; 78(1): 98 - 107.
[Abstract] [Full Text] [PDF]